Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor
Patrick A Flume, Claire E Wainwright, D Elizabeth Tullis, Sally Rodriguez, Minoo Niknian, Mark Higgins, Jane C Davies, Jeffrey S Wagener, Patrick A Flume, Claire E Wainwright, D Elizabeth Tullis, Sally Rodriguez, Minoo Niknian, Mark Higgins, Jane C Davies, Jeffrey S Wagener
Abstract
Background: Pulmonary exacerbations (PEx) are associated with acute loss of lung function that is often not recovered after treatment. We investigated lung function recovery following PEx for ivacaftor- and placebo-treated subjects.
Methods: Short- and long-term pulmonary function recovery data after PEx were summarized from a placebo-controlled trial in 161 cystic fibrosis patients≥12years old with the G551D-CFTR mutation (NCT00909532). Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both compared with baseline measured just prior to the PEx.
Results: Fewer patients receiving ivacaftor experienced a PEx than patients receiving placebo (33.7% vs. 56.4%; P=0.004) and had a lower adjusted incidence rate of PEx (0.589 vs. 1.382; P<0.001). The proportion of PEx followed by full short-term recovery of percent predicted forced expiratory volume in 1s was similar (ivacaftor vs. placebo, 57.1% vs. 53.7), as was the proportion of patients having long-term recovery (46.4% vs. 47.7%).
Conclusions: Ivacaftor treatment reduces the frequency of PEx but does not improve on the rate of complete lung function recovery after PEx when compared with placebo.
Keywords: Cystic fibrosis; Cystic fibrosis transmembrane conductance regulator; Ivacaftor; Pulmonary exacerbations; Pulmonary function.
Copyright © 2017 European Cystic Fibrosis Society. All rights reserved.
Source: PubMed